أخبار إنجليزية حسب المستوى

FDA Set to Decide on At-Home Weekly Injection of Lecanemab for Early Alzheimer's

The U.S. Food and Drug Administration is expected to rule this month on whether to approve a subcutaneous, at-home version of lecanemab, marketed as Leqembi Iqlik, for patients with mild cognitive impairment or mild dementia from Alzheimer's disease. If cleared, the once-weekly auto-injector would let many patients skip biweekly hospital infusions and bring an Alzheimer's therapy into the kitchen for the first time.